Introduction
The purpose of this article is to explore the benefits of using decision analysis in clinical decision making when the published evidence about the effectiveness of an intervention is uncertain. The use of decision analysis will be explored using the example of aciclovir prophylaxis in late pregnancy for women with recurrent genital herpes infection. ' The article draws on the guidelines published by Richardson and others which set out a framework for evaluating the usefulness of a clinical decision analysis model (table 1).2 3 National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford OX2 6HE P Brocklehurst T 
Roberts
Accepted for publication 7 May 1997 THE CLINICAL PROBLEM Women with genital herpes infection in pregnancy are at risk of transmitting herpes to their baby at the time of delivery resulting in neonatal herpes infection. Neonatal herpes is a severe illness with a high mortality and morbidity even with prompt antiviral treatment. 4 Current management of women with recurrent genital herpes infection during pregnancy in the UK rests almost entirely on whether the woman experiences a symptomatic recurrence at the time of labour. If there is evidence of an active recurrence then delivery by caesarean section is recommended to avoid the risk of mother to child transmission. 5 If there is no evidence of an active recurrence then a vaginal delivery is anticipated. The risk of mother to child transmission is unknown but estimates suggest that it can be no higher than 8%6 although many authorities believe it is significantly lower than this and some have suggested that it is negligible.7 As a consequence of the current management policy many women with recurrent genital herpes infection present at the time of labour undergo caesarean section when the risk to the neonate appears to be small. An alternative management strategy which has been suggested is the use of suppressive aciclovir starting in late pregnancy, usually around 36 weeks, to pre 
THE EVIDENCE FOR ACICLOVIR SUPPRESSION
A Medline search for randomised trials which evaluate the effectiveness of aciclovir suppression in late pregnancy will reveal only one .9 This was conducted in women experiencing their first episode of genital herpes infection during the index pregnancy. The trial demonstrated a decrease in the incidence of caesarean section in the women receiving aciclovir. The generalisability of these results to women with pre-existing recurrent herpes infection is not straightforward. It is possible that subsequent recurrences during the pregnancy in these women are more frequent and/or more severe than those experienced by women with pre-existing herpes infection. In addition, it appears that these women are at a substantially increased risk of mother to child transmission and other adverse neonatal outcomes than women with pre-existing infection. ' The chance and decision nodes of the decision tree need to be accompanied by probabilities that either pathway will be followed depending on the preceding event. Probabilities will need to be assembled from a broad range of information in the medical literature. In order to determine the probabilities it is necessary to review critically a large volume of information using the processes already described in this series so that only those studies where the methods are valid are incorporated. The literature review should be systematic and clearly explained if bias is to be avoided.'3 The paper by Randolph et al does not specify the search strategy or search terms used to search Medline, nor does it specify the process of selection of the studies. The paper clearly states that "the baseline probability values were the most plausible estimates". This statement could be interpreted as suggesting that the authors only included those articles which reported estimates which agreed with their existing views. A clearer description of the selection process would help to satisfy those worried about this statement and how this may contribute to selection bias. If the analysis is being taken beyond a partial analysis, as in the paper by Randolph et al, to a complete cost utility analysis then there may need to be interviews with patient groups Once the authors have decided what information to include they must synthesise it into a quantitative estimate of each probability. Depending on the source of this information these probabilities may come with some uncertainty, in which case a range of probabilities may be incorporated into the model (see below). It is often useful in these publications to indicate the strength of the evidence which has been used to provide these probability estimates. For aciclovir prophylaxis in late pregnancy the authors have devised a scale from A to D which assesses the quality of the evidence resulting in their baseline probability values. Grade A was from data with a high level of confidence-for example, randomised controlled trials or multicentre cohort studies with consistent findings, through to grade D which was a best guess with no data available. The authors assembled an impressive list of probabilities with ranges. There are two probability estimates, however, which are particularly crucial to the decision tree and both these are the decision nodes. The first is the effectiveness of aciclovir at preventing lesions at the time of labour and hence preventing delivery by caesarean section. The second is the effectiveness of caesarean section at preventing mother to child transmission. These probabilities are essential in this decision tree. As has already been discussed, however, there are no randomised controlled trials of the effectiveness of aciclovir in this population of women and there are no large multicentre cohort studies addressing this question. Therefore, the probabilities used for the effectiveness of aciclovir could be considered to be weaker than is suggested by the paper. Uncertainty in probability estimates can be expressed by a range of estimates. A sensitivity analysis can then be carried out by substituting the highest and lowest values for the probabilities which were included in the original model. Which probability estimates should be varied will be a matter of judgment and this will depend to an extent on the level of certainty of the estimate. The sensitivity analyses in the paper by Randolph et al varied three factors. The first of these was the effectiveness of aciclovir which ranged from 45% to 95%. As has already been discussed, however, the estimate of effectiveness of aciclovir has not been determined in this population of women. The range of probabilities given assumes that aciclovir is effective (the lowest estimate used is 45%). It may have been more appropriate to vary these limits between the highest estimate and 0%. The remaining factors in the sensitivity analyses include altering the mother to child transmission risk at vaginal delivery to 4% (from the original model which included an estimate of 1 %) and altering the effectiveness of caesarean section at preventing mother to child transmission from 80% to 0%. The four strategies investigated were compared to explore the effect each had on the number of cases of neonatal herpes infection which could be averted per 10 000 women. The strategy which was most effective in this decision analysis was that of aciclovir with caesarean section if The more precise the estimates of probabilities the more likely a sensitivity analysis is to produce a similar result to the original model. The less robust the evidence, however, the more likely a sensitivity analysis is to produce a model with a differing result and interpretation. The paper by Randolph et al includes the effectiveness of aciclovir, the mother to child transmission rate, and the effectiveness of caesarean section in separate sensitivity analyses Resolution of the scenario Without a good and relevant randomised controlled trial of the effectiveness of aciclovir in women with recurrent genital herpes infection your ability to decide the most effective management for your patient will be limited. Aciclovir is not licensed for use in pregnancy and although no long term side effects have been reported with its use the lack of strong data supporting its effectiveness has to be taken into consideration when assessing the usefulness of this decision analysis.
The decision analysis however has been useful in defining those parts of the clinical pathway which are important and where more robust information needs to be obtained before firm recommendations can be given. Until that time, however, the decision analysis, by making the process explicit, should have made you much better informed and better able to judge how to manage your patients.
